

MolMed wins the patent litigation related to TK therapy

Milan (Italy), 22 October 2009 - MolMed S.p.A. (Milan:MLM) announces that the Court of Milan, with a decision filed on October 21, entirely rejected all the claims filed by LTK Farma s.a.s. and Université Pierre et Marie Curie, in a patent litigation started against MolMed for the alleged infringement of their European patent EP 0564646.

The patent litigation, commenced on June 7, 2007, concerned the clinical development activities of MolMed's investigational therapy TK. The patent suit was included among the "risk factors" in MolMed's IPO Offering Circular dated February 15, 2008 (see pages 25, 96-97, 198, 237 and 276 of the Offering Circular), and mentioned as possible "contingent liability" in all subsequent annual financial statements and interim financial reports.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemias; NGR-hTNF, a novel vascular targeting agent (VTA), in Phase II in six different indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancers, and malignant pleural mesothelioma. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares (Milan:MLM) are listed on the Milan Stock Exchange, at the Standard segment (class I) of the MTA managed by Borsa Italiana.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999 as subsequently amended.

DISCLAIMER

This press release may contain certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.

For further information, please contact:

Holger Neecke
Director Business Development, Investor Relations
MolMed S.p.A.
phone: +39 02 21277.205
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Elena Lungagnani
Communication Manager
MolMed S.p.A.
phone: +39 02 21277.207
fax: +39 02 21277.325
e-mail: media.relations@molmed.com